June Ye
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Systemic Lupus Erythematosus Research, Rheumatoid Arthritis Research and Therapies, Diabetes Management and Research, Metabolism, Diabetes, and Cancer
Most-Cited Works
- → Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study(2014)320 cited
- → Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)*(2019)232 cited
- → Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab(2019)184 cited
- → HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea(2014)130 cited
- → Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis(2015)79 cited
- → Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes(2012)52 cited
- → Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study(2018)48 cited
- → Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial(2022)47 cited
- → Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis(2017)32 cited
- → A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus(2014)30 cited